Beta Amyloid Antibodies and Antigens for Alzheimer's Research
The beta amyloid antibody targets amyloid plaques, a key Alzheimer's disease hallmark. Engineered to
recognize and neutralize amyloid proteins, these antibodies potentially slow the disease's progression by
preventing plaque formation in the brain, representing a significant stride in Alzheimer's research and
therapeutic approaches, aiming to improve patient care and outcomes.
| Catalog No. | Products Name | Biomarker | Fc/Tag | Products Information |
| GMP-h-Aβ42-Ab | Anti-human Aβ42 monoclonal antibody (mAb) | beta-amyloid 42 (Aβ42) | hFc/mFc | Details |
| GMP-h-Aβ40-Ab | Anti-human Aβ40 monoclonal antibody (mAb) | beta-amyloid 40 (Aβ40) | hFc/mFc | Details |
| GMP-h-Aβ42-Ag01 | Beta-amyloid 42 (Aβ42) antigen | beta-amyloid 42 (Aβ42) | Details | |
| GMP-h-Aβ40-Ag01 | Beta-amyloid 40 (Aβ40) antigen | beta-amyloid 40 (Aβ40) | Details |
Validation of GeneMedi's Aβ40/Aβ42 products
The high-performance Aβ40 and Aβ42 antibody raw materials developed by GeneMedi have the advantages of good specificity and high sensitivity, and are the preferred raw materials for the development of in vitro diagnostic reagents for Alzheimer's disease.
- Figure 1: ELISA Validation Aβ40/Aβ42 antibody
- Figure 2: CLIA Validation Aβ40/Aβ42 antibody
Figure 1. ELISA Validation of GeneMedi's Aβ40/Aβ42 antibody
Indirect ELISA analysis of clone [B], [A]
and [A] antibody specificity, [B] and [A] can Recognizes Aβ40, while [A] has no cross-reactivity
with
Aβ40 Picture indirect ELISA analysis of cloned [B], [A] and [A] antibody specificity. [B] and [A]
can
recognize Aβ42 , while [A] has no cross-reaction with Aβ42.
A: GMP-h-Aβ42-Ab01
B: GMP-h-Aβ42-Ab02
The high-performance Aβ40 and Aβ42 antibody raw materials developed by GeneMedi have the
advantages of good
specificity and high sensitivity, and are the preferred raw materials for the development of in
vitro
diagnostics reagents for Alzheimer's disease.
Figure 2. CLIA verification data of GeneMedi's Aβ40/Aβ42 antibody
Beta-amyloid(1-42) antibodies (GMP-h-Aβ42-Ab02 and GMP-h-Aβ42-Ab01) established a standard curve by chemiluminescence method, and the detection range of Aβ42 was 100-1700 pg/mL.
Understanding Beta Amyloid
The 2023 Alzheimer's Association International Conference (AAIC) released a draft proposal for AD diagnostic standards, which introduces blood-based biomarker testing for the first time. AD can be diagnosed through plasma markers such as Aβ42, Aβ40, P-tau181, P-tau217, P-tau231, NFL, GFAP (as shown in the table above). These markers have not yet been subjected to large-scale clinical studies, and relevant groups need to be Do further analysis. For the diagnosis of AD, it is necessary to rely on comprehensive methods such as clinical manifestations and imaging.
Aβ40 polypeptide and Aβ42 polypeptide are common forms found in human cerebrospinal fluid and serum. It is generally believed that Aβ42 peptide has stronger neurotoxicity and is more prone to aggregation. Changes in Aβ42 peptide concentration in human cerebrospinal fluid and blood are associated with Alzheimer's disease.
Beta Amyloid is produced by the hydrolysis of amyloid precursor protein (APP) by β and γ secretases and is composed of 38-43 amino acids with toxic effects (as shown on the right ).
Eli Lilly's new drug Donanemab is an investigational drug for the treatment of AD. It is a specific antibody targeting the N-terminal pyroglutamate Aβ epitope of amyloid plaques. Donanemab antibody can significantly reduce blood pTau217 levels. A significant decrease in plasma pTau217 levels was observed after 12 weeks of treatment with donanemab compared with placebo and was sustained throughout the 76 weeks of the study.
Mean plasma pTau217 levels in the donanemab treatment group decreased by 23% from baseline. In contrast, mean plasma pTau217 levels in the placebo group continued to increase by 6% from baseline to the end of the study, as shown below. pTau217 may become a companion diagnostic indicator in the treatment of AD by Donanemab.
Facebook
LinkedIn
Twitter
